Inovio Pharmaceuticals is COVID-19’s Theranos: Citron

inovio pharmaceuticals covid-19geralt / Pixabay

Citron Research is targeting another company. This time it’s Inovio Pharmaceuticals, which the firm compared to Theranos during COVID-19. In a report posted on its website, Citron said that like Theranos, Inovio Pharmaceuticals Inc (NASDAQ: INO) claims to have a “secret sauce” that “supposedly developed a vaccine for COVID-19 in just 3 hours.”

Get The Full Ray Dalio Series in PDF

Get the entire 10-part series on Ray Dalio in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues

Q1 2020 hedge fund letters, conferences and more

The firm goes on to argue that Inovio investors have been "Theranosed" and that the Securities and Exchange Commission "should immediately halt this blatant stock promotion."

Inovio Pharmaceuticals reveals algorithm

Citron describes Inovio's management team as "a group of charlatans." The firm drew attention to a 60 Minutes interview with Kate Broderick, the company's SVP of research and development. She said they used a computer algorithm to design a vaccine for COVID-19. After just three hours, she claimed they had "a fully designed vaccine on paper."

However, this computer algorithm that can supposedly design a COVID-19 vaccine in only three hours isn't mentioned on any of Inovio Pharmaceuticals' 10-K or 10-Q filings. Citron said that makes the situation sound like what happened to Theranos.

Stock promotion

The firm went on to describe Inovio Pharmaceuticals as "one of the longest running and most blatant stock promotion schemes" it has ever witnessed.

"The company has a well-documented history of issuing press releases saying they will have the first and best vaccine for whatever infectious disease is in the news headlines during that time," Citron wrote. "These press releases are followed by highly dilutive stock offerings and large insider sales."

The firm also pointed to several press releases in which Inovio claimed to have vaccines for other diseases, like the Zika virus. Citron said like with many publicly traded drug makers, Inovio's stock spikes whenever it releases positive study results, although it generally sees "little if anything of commercial substance arise out of those studies."

Citron also pointed to a 2009 article that said Inovio Pharmaceuticals has "a habit of issuing fresh shares either to the public or in private placements that often appears synced to its study-result bulletins and stock-price upticks."

COVID-19 vaccine in the works

Inovio Pharmaceuticals began Phase 1 clinical trials for its COVID-19 vaccine this month. The first phase will determine whether the vaccine is safe, but it doesn't say anything about whether it's effective. Based on its track record around other Phase 1 clinical trials for other infectious diseases, Citron expects the company to announce positive data from the Phase 1 trial. However, that expectation doesn't change its view of the drug maker.

The company issued a press release on March 3 saying that it expects to have 1 million COVID-19 vaccines by the end of this year. However, its FDA filing indicates that the test won't even be done until next year in a best-case scenario.

"Not a single one of the many promised vaccines has EVER come to market in over 40 years!" Citron wrote. "This is the same platform and same scientific team that has been fleecing investors for decades with promotional press releases and highly dilutive stock offerings."

For exclusive info on hedge funds and the latest news from value investing world at only a few dollars a month check out ValueWalk Premium right here.

Multiple people interested? Check out our new corporate plan right here (We are currently offering a major discount)



About the Author

Michelle Jones
Michelle Jones was a television news producer for eight years. She produced the morning news programs for the NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spent a short time at the CBS affiliate in Huntsville. She has experience as a writer and public relations expert for a wide variety of businesses. Michelle has been with ValueWalk since 2012 and is now our editor-in-chief. Email her at Mjones@valuewalk.com.

Be the first to comment on "Inovio Pharmaceuticals is COVID-19’s Theranos: Citron"

Leave a comment